Irradiated tumor cell vaccine engineered to express GM-CSF

US5637483A · kind A · utility

Assignees

• Whitehead Institute For Biomedical Research · US
• The Johns Hopkins University School of Medicine · US

Inventors

• Glenn Dranoff · Lexington, US
• Richard C. Mulligan · Cambridge, US
• Drew M. Pardoll · Silver Spring, US

Key dates

• Filing date: Jun 23, 1994
• Grant date: Jun 10, 1997
• Expiry date: Jun 23, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/13043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.